U.S. Drug Shortages Worsen to Reach a Decade High: Report

Seeking AlphaJun 15 23:19

Sandoz Receives European Commission Approval for Wyost and Jubbonti, the First and Only Biosimilars of Denosumab in Europe

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost (denosumab) and Jubbonti (denosumab) approved by EC for all indications of

GlobeNewswireMay 22 13:00

Individual Investors Who Own 60% Along With Institutions Invested in Sandoz Group AG (VTX:SDZ) Saw Increase in Their Holdings Value Last Week

Yahoo FinanceMay 11 16:29

Sandoz Q1 Sales $2.492B Up From $2.384B YoY

Strong first quarter performance, with net sales1 of USD 2.5 billion, up 6% in constant currencies (up 5% in USD)− Biosimilar business growing 21% in constant currencies − All regions contributing t

BenzingaMay 7 15:11

Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab

Generic and biosimilar manufacturer Sandoz AG (OTC:SDZNY) (OTC:SDZXF) reached an agreement on Tuesday with Amgen Inc (NASDAQ:AMGN) to resolve all patent litigation related to its U.S. denosumab biosim

BenzingaApr 30 23:54

Sandoz Confirms European Commission Approval of Pyzchiva (Ustekinumab), Further Strengthening Immunology Offering

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva approved as one of first ustekinumab biosimilars in EuropeEC approval based on robust development program confirming match to

GlobeNewswireApr 22 13:00